FK506-binding protein 12 ligands: A patent review

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 11, 2013, Pages 1435-1449

  Liu, Fei ^a,b   Wang, Yong Qing ^a   Meng, Ling ^a   Gu, Min ^a   Tan, Ruo Yun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Ascomycin; Calcineurin; FK506; FKBP12; MTOR; Rapamycin; Small ligands

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; ANTASCOMICIN A; ANTASCOMICIN B; ANTASCOMICIN C; ANTASCOMICIN D; ANTASCOMICIN E; ASCOMYCIN; BICALUTAMIDE; CYCLOHEXIMIDE; CYCLOSPORIN; CYTOPLASM PROTEIN; EVEROLIMUS; EYE DROPS; FKBP12 PROTEIN; IMMUNOSUPPRESSIVE AGENT; LACTONE DERIVATIVE; MERIDAMYCIN; PIMECROLIMUS; PREDNISOLONE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RIDAFOROLIMUS; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; V 10367; WAY 124466;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATOPIC DERMATITIS; ATROPHY; BINDING AFFINITY; CASTRATION RESISTANT PROSTATE CANCER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; ENDOMETRIUM CANCER; GRAFT REJECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY CARCINOMA; MYASTHENIA GRAVIS; NEUROENDOCRINE TUMOR; NEUROPROTECTION; PARKINSON DISEASE; PROSTATE CANCER; REVIEW; SKIN DISEASE; STEADY STATE; TABLET COMPRESSION; THYMECTOMY; TREATMENT FAILURE; VISUAL DISORDER;

ANIMALS; ANTINEOPLASTIC AGENTS; DERMATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; NEUROPROTECTIVE AGENTS; PATENTS AS TOPIC; SIROLIMUS; SMALL MOLECULE LIBRARIES; TACROLIMUS; TACROLIMUS BINDING PROTEIN 1A; VISION DISORDERS;

EID: 84886931375     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.828695     Document Type: Review

References (112)

1. Zhang J, Nakatsu Y, Sinjo T, et al. Par14 associates with IRS-1, thereby enhancing insulin-induced IRS-1 phosphorylation and metabolic actions. J Biol Chem 2013; published online 29 May 2013; doi: 10.1074/jbc. M113.485730
2. Somarelli J, Lee S, Skolnick J, et al. Structure-based classification of 45 FK506-binding proteins. Proteins 2008;72:197-208
3. Nakamura K, Kosugi I, Lee DY, et al. Prolyl isomerase Pin1 regulates neuronal differentiation via beta-catenin. Mol Cell Biol 2012;32:2966-78
4. Teng BL, Hacker KE, Chen S, et al. Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma. Mol Oncol 2011;5:465-74
5. Kang CB, Hong Y, Dhe-Paganon S, et al. FKBP family proteins: Immunophilins with versatile biological functions. Neurosignals 2008;16:318-25
6. Aghdasi B, Ye K, Resnick A, et al. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acade Sci 2001;98:2425-30
7. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 1996;7:93-102
8. Stockwell BR, Schreiber SL. TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. Chem Biol 1998;5:385-95
9. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700
10. Cameron AM, Steiner JP, Sabatini DM, et al. Immunophilin FK506 binding protein associated with inositol 1, 4, 5-trisphosphate receptor modulates calcium flux. Proc Natl Acad Sci 1995;92:1784-8
11. Mathea S, Li S, Schierhorn A, et al. Suppression of EGFR autophosphorylation by FKBP12. Biochemistry 2011;50:10844-50
12. Lopez-Ilasaca M, Schiene C, Küllertz G, et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J Biol Chem 1998;273:9430-4
13. Hemenway CS, Heitman J. Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. J Biol Chem 1996;271:18527-34
14. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996;76:631-49
15. Wu X, Wang L, Han Y, et al. Creating diverse target-binding surfaces on FKBP12: Synthesis and evaluation of a rapamycin analogue library. ACS Comb Sci 2011;13:486-95
16. Carroll CL, Fleischer J, Alan B. Tacrolimus ointment: The treatment of atopic dermatitis and other inflammatory cutaneous disease. Expert Opin Pharmacother 2004;5:2127-37
17. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34
18. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20:233-41
19. Wei TQ, Hudson DR. Tacrolimus standard and methods of using same. US008153594B2; 2012
20. Sikkink R, Haddy A, MacKelvie S, et al. Calcineurin subunit interactions: Mapping the calcineurin B binding domain on calcineurin A. Biochemistry 1995;34:8348-56
21. Weiwad M, Edlich F, Kilka S, et al. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006;45:15776-84
22. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000;7:731-48
23. Hamawy MM, Knechtle SJ. An overview of the actions of cyclosporine and FK506. Transplant Rev 2003;17:165-71
24. Choi J, Chen J, Schreiber SL, et al. Structure of the FKBP12-rapamycin complex interacting with binding domain of human FRAP. Science 1996;273:239-42
25. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991;23:2977-83
26. Calderón-Sánchez E, Rodriguez-Moyano M, Smani T. Immunophilins and cardiovascular complications. Curr Med Chem 2011;18:5408-13
27. Szabó L, Szentandrássy N, Kistamás K, et al. Effects of tacrolimus on action potential configuration and transmembrane ion currents in canine ventricular cells. Naunyn Schmiedebergs Arch Pharmacol 2013;386:239-46
28. Zadrazil J, Horak P, Zahalkova J, et al. Improvement of cardiovascular risk factors and cosmetic side effects in kidney transplant recipients after conversion to tacrolimus. Biomed Pap 2009;153:67-73
29. Hohage H, Welling U, Heck M, et al. Conversion from cyclosporine to tacrolimus after renal transplantation improves cardiovascular risk factors. Int Immunopharmacol 2005;5:117-23
30. Desai S, Hong JC, Saab S. Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management. Liver Int 2010;30:948-57
31. Gordon RD, Holm P, Lademann AM, et al. Tacrolimus for improved treatment of transplant patients. US20120029009Al; 2012
32. Wakata N, Saito T, Tanaka S, et al. Tacrolimus hydrate (FK506): Therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin Neurol Neurosurg 2003;106:5-8
33. Guo X, Dillman JF, Dawson VL, et al. Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Neurol Prog 2001;50:6-16
34. Yao Z, Wu H. A method of FK506 release membrane preparation for nerve injury repairment. CN2008102285753; 2008
35. Takashi U. The vision cell dysfunction therapeutic agent. CN998162760; 1999
36. Pople PV, Singh KK. Targeting tacrolimus to deeper layers of skin with improved safety for treatment of atopic dermatitis. Int J Pharm 2010;398:165-78
37. Bierer BE, Somers PK, Wandless TJ, et al. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 1990;250:556-9
38. Reeves C, Chu D, Khosla C, et al. Polynucleotides encoding the fkbA gene of the FK-520 polyketide synthase gene cluster. US006759536B2; 2004
39. Dumont FJ, Staruch M, Koprak S, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992;176:751-60
40. März AM, Fabian A-K, Kozany C, et al. Large FK506-binding proteins shape the pharmacology of rapamycin. Mol Cell Biol 2013;33:1357-67
41. Powell JD, Pollizzi KN, Heikamp EB, et al. Regulation of immune responses by mTOR. Annu Rev Immunol 2012;30:39-68
42. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8+ T-cell differentiation. Immunol Rev 2010;235:234-43
43. Waickman AT, Powell JD. mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev 2012;249:43-58
44. Danielpour D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 2005;41:846-57
45. Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/ mTORC2 inhibitors. Cancer Res 2011;71:1573-83
46. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncol 2011;6:17-27
47. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: MTORC2 and beyond. Sci Signal 2009;2:pe27
48. Garcia-Martinez J, Alessi D. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum-And glucocorticoidinduced protein kinase 1 (SGK1). Biochem J 2008;416:375-85
49. Hong F, Larrea MD, Doughty C, et al. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 2008;30:701-11
50. Janes MR, Fruman DA. Targeting TOR dependence in cancer. Oncotarget 2010;1:69-76
51. Chaturvedi D, Gao X, Cohen MS, et al. Rapamycin induces transactivation of the EGFR and increases cell survival. Oncogene 2009;28:1187-96
52. Naing A. Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Expert Opin Investig Drugs 2013;22:679-85
53. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41
54. McMullen JR, Sherwood MC, Tarnavski O, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 2004;109:3050-5
55. Azroland NI, Segal SN. Methods for the treatment of cardiovascular disease. CN018112129; 2001
56. Tsang CK, Qi H, Liu LF, et al. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-24
57. Serruys PW, Kutryk MJB, Ong ATL. Coronary-Artery stents. N Engl J Med 2006;354:483-95
58. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
59. Vezina C, Kudelski A, Sehgal S. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6
60. Sehgal S, Baker H, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32
61. Chen G, Zheng H, Deng J. An acne endermic agent. CN201210013571X; 2012
62. Steiner JP, Snyder S, Hamilton GS, et al. Inhibitors of rotamase enzyme activity. US20030114365Al; 2003
63. Roberts M, Arabshahi L, Boyd J, et al. Immunoassays for everolimus. US007223553B2; 2007
64. Houghton PJ. Everolimus. Clin Cancer Res 2010;16:1368-72
65. Bukowski RM. Temsirolimus: A safety and efficacy review. Expert Opin Drug Saf 2012;11:861-79
66. Rubino JT, Siskavich V, Harrison MM, et al. Parenteral formulations. US20110294845Al; 2011
67. Rivera VM, Squillace RM, Miller D, et al. Ridaforolimus (AP23573; MK- 8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther 2011;10:1059-71
68. Vladyka RS, Dalgarno DC, Iuliucci JD. Oral formulations. US20100247643Al; 2010
69. Colombo N, McMeekin D, Schwartz P, et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-Arm, phase 2 trial. Br J Cancer 2013;108(5):1021-6
70. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013;31(19):2485-92
71. Ebbinghaus S. Combination therapy. WO2010044893; 2010
72. Reeves CD, Chung LM, Liu Y, et al. A new substrate specificity for acyl transferase domains of the ascomycin polyketide synthase in Streptomyces hygroscopicus. J Biol Chem 2002;277:9155-9
73. Chakraborty T, Weber H, Nicolaou K. Design and Synthesis of a rapamycin-based high affinity binding FKBP12 ligand. Chem Biol 1995;2:157-61
74. Gyollai V, Szabo C. Methods for preparing pimecrolimus. WO2006060614A1; 2006
75. Hoetzenecker W, Ecker R, Kopp T, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005;115:1276-83
76. Assmann T, Homey B, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000;47:203-13
77. Gupta A, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol 2003;17:493-503
78. Salituro GM, Zink DL, Dahl A, et al. Meridamycin: A novel nonimmunosuppressive FKBP12 ligand from streptomyces hygroscopicus. Tetrahedron Lett 1995;36:997-1000
79. Graziani EI, Pong K. Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents. US20050197356Al; 2005
80. Gregory MA, Gaisser S, Petkovic H, et al. Production of polyketides and other natural products. US20080287482A; 2008
81. Fehr T, Sanglier JJ, Schuler W, et al. Antascomicins A, B, C, D and E novel FKBP12 binding compounds from a Micromonospora strain. J Antibiot (Tokyo) 1996;49:230-3
82. Blackburn EA, Walkinshaw MD. Targeting FKBP isoforms with small-molecule ligands. Curr Opin Pharmacol 2011;11:365-71
83. Gold BG, Armistead DM, Wang MS. Non-FK506-binding protein-12 neuroimmunophilin ligands increase neurite elongation and accelerate nerve regeneration. J Neurosci Res 2005;80:56-65
84. Gold BG, Densmore V, Shou W, et al. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 1999;289:1202-10
85. Quintá H, Galigniana M. The neuroregenerative mechanism mediated by the Hsp90-binding immunophilin FKBP52 resembles the early steps of neuronal differentiation. Br J Pharmacol 2012;166:637-49
86. Armistead DM. Methods and compositions for stimulating neurite growth. US006037370A; 2000
87. Mutz MW, Gestwicki JE. Combinatorial improvement of bifunctional drug properties. US20090054334Al; 2009
88. Babine RE, Villafranca JE, Gold BG. FKBP immunophilin patents for neurological disorders. Expert Opin Ther Patents 2005;15:555-73
89. Gaali S, Gopalakrishnan R, Wang Y, et al. The chemical biology of immunophilin ligands. Curr Med Chem 2011;18:5355-79
90. Klettner A, Herdegen T. The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. Br J Pharmacol 2003;138:1004-12
91. Klettner A, Baumgrass R, Zhang Y, et al. The neuroprotective actions of FK506 binding protein ligands: Neuronal survival is triggered by de novo RNA synthesis, but is independent of inhibition of JNK and calcineurin. Mol Brain Res 2001;97:21-31
92. Sauer H, Francis JM, Jiang H, et al. Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice. Brain Res 1999;842:109-18
93. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci 1997;94:2019-24
94. Marshall V, Grosset D. GPI-1485 (Guilford). Curr Opin Investig Drugs (London, England: 2000) 2004;5:107-12
95. Ninds N-P. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8
96. Ross DT, Hamilton GS, Steiner JP. Heterocyclic esters or amides for vision and memory disorders. US007338976Bl; 2008
97. Choi C, Li JH, Vaal M, et al. Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors. Bioorg Med Chem Lett 2002;12:1421-8
98. Kosley RW Jr, Baron B, Jimonet P, et al. FKBP binding composition and pharmaceutical use thereof. WO2006012256; 2006
99. Vrudhula VM, Dubowchik GM, Dasgupta B, et al. Neurotrophic difluoroamide agents. US006239146Bl; 2001
100. Kemp MI, Palmer MJ, Sanner MA, et al. Heterocyclic compounds as inhibitors of rotamase enzymes. US006562964B1; 2003
101. Harper S, Bilsland J, Young L, et al. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience 1999;88:257-67
102. Bocquet A, Lorent G, Fuks B, et al. Failure of GPI compounds to display neurotrophic activity in vitro and in vivo. Eur J Pharmacol 2001;415:173-80
103. Martina MR, Tenori E, Bizzarri M, et al. The precise chemical-physical nature of the pharmacore in FK506 binding protein inhibition: ElteX, a new class of nanomolar FKBP12 ligands. J Med Chem 2013;56:1041-51
104. Christner C, Wyrwa R, Marsch S, et al. Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties. J Med Chem 1999;42:3615-22
105. Edlich F, Weiwad M, Wildemann D, et al. The specific FKBP38 inhibitor N- (N¢, N¢-dimethylcarboxamidomethyl) cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem 2006;281:14961-70
106. Gopalakrishnan R, Kozany C, Gaali S, et al. Evaluation of Synthetic FK506 Analogues as Ligands for the FK506-Binding Proteins 51 and 52. J Med Chem 2012;55:4114-22
107. Limburg DC, Thomas BE IV, Li JH, et al. Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands. Bioorg Med Chem Lett 2003;13:3867-70
108. Dubowchik GM, Provencal DP. Neurotrophic bicyclic diamides. US006818643Bl; 2004
109. Wang Y, Kirschner A, Fabian A-K, et al. Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control. J Med Chem 2013;56:3922-35
110. Burkhard P, Hommel U, Sanner M, et al. The discovery of steroids and other novel FKBP inhibitors using a molecular docking program. J Mol Biol 1999;287:853-8
111. Steiner JP, Snyder S, Hamilton GS, et al. Inhibitors of rotamase enzyme activity. US006500843B2; 2002
112. Jin YJ Albers MW Lane WS et al. Molecular cloning of a Membrane-Associated Human FK506-And Rapamycin-binding Protein FKBP-13. Proc Natl Acad Sci 1991;886677-81